Systemic hypotension following intravenous administration of contrast medium during computed tomography.

Innsbruck Medical University, Department of Radiology, Section of Microinvasive Therapy0 个研究点开始时间: 2014年9月22日最近更新: 2015年10月26日

试验速览

暂无简介。

•Primary or secondary liver tumors treatable by SRFA.
•Approval of an interdisciplinary cancer board for SRFA.
•Adult patients > 18 years, American Society of Anesthesiologists (ASA) score I-III, scheduled for radiological interventions with CM (obligate application) under general anesthesia.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) no
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 10

•Reduced mental status of the patient, history of psychiatric disorder, refusal by patient, failure to obtain written and informed consent.
•Primary or secondary liver tumors larger than 12 cm in diameter or prediction of insufficient liver remnant, more than 7 lesions, lesions within 1 cm distance to the central bile duct, lesions infiltrating adjacent hollow viscera.
•Liver cirrhosis classified higher than Child-Pugh class B, manifest ascites.
•Estimated glomerular filtration rate (eGFR) <45.
•Clotting disorders (PT < 50%, apTT >50 sec and thrombocytes < 50,000/mm3) or recent intake of platelet aggregation inhibitors
•Evidence of intolerance or allergic reactions against both CM.
•Contraindications to both CM according to Austrian Fachinformation
•Antihypertensive treatment except Midazolam (Dormicum®, Roche Pharmaceutics, Vienna, Austria) orally 30 minutes prior to surgery at dose between 3.75 and 7.5 mg.

发起方

Innsbruck Medical University, Department of Radiology, Section of Microinvasive Therapy